|
1
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Husein B, Abdalla M, Trepte M, Deremer
DL and Somanath PR: Antiangiogenic therapy for cancer: an update.
Pharmacotherapy. 32:1095–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Young RJ and Reed MW: Anti-angiogenic
therapy: concept to clinic. Microcirculation. 19:115–125. 2012.
View Article : Google Scholar
|
|
6
|
Wu JM and Staton CA: Anti-angiogenic drug
discovery: lessons from the past and thoughts for the future.
Expert Opin Drug Discov. 7:723–743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kerbel RS: Inhibition of tumor
angiogenesis as a strategy to circumvent acquired resistance to
anti-cancer therapeutic agents. Bioessays. 13:31–36. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boehm T, Folkman J, Browder T and O’Reilly
MS: Antiangiogenic therapy of experimental cancer does not induce
acquired drug resistance. Nature. 390:404–407. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sweeney CJ, Miller KD and Sledge GW Jr:
Resistance in the anti-angiogenic era: nay-saying or a word of
caution? Trends Mol Med. 9:24–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Broxterman HJ, Lankelma J and Hoekman K:
Resistance to cytotoxic and anti-angiogenic anticancer agents:
similarities and differences. Drug Resist Updat. 6:111–127. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giuliano S and Pagès G: Mechanisms of
resistance to anti-angiogenesis therapies. Biochimie. 95:1110–1119.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang L, Perrault C, Coelho-Martins J, et
al: Induction of acquired drug resistance in endothelial cells and
its involvement in anticancer therapy. J Hematol Oncol. 6:492013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hida K, Akiyama K, Ohga N, Maishi N and
Hida Y: Tumour endothelial cells acquire drug resistance in a
tumour microenvironment. J Biochem. 153:243–249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pakos EE and Ioannidis JP: The association
of P-glycoprotein with response to chemotherapy and clinical
outcome in patients with osteosarcoma. A meta-analysis. Cancer.
98:581–589. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akiyama K, Ohga N, Hida Y, et al: Tumor
endothelial cells acquire drug resistance by MDR1 up-regulation via
VEGF signaling in tumor microenvironment. Am J Pathol.
180:1283–1293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lage H and Dietel M: Effect of the
breast-cancer resistance protein on atypical multidrug resistance.
Lancet Oncol. 1:169–175. 2000. View Article : Google Scholar
|
|
17
|
Xu J, Peng H and Zhang JT: Human multidrug
transporter ABCG2, a target for sensitizing drug resistance in
cancer chemotherapy. Curr Med Chem. 14:689–701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ni Z, Bikadi Z, Rosenberg MF and Mao Q:
Structure and function of the human breast cancer resistance
protein (BCRP/ABCG2). Curr Drug Metab. 11:603–617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cooray HC, Blackmore CG, Maskell L and
Barrand MA: Localisation of breast cancer resistance protein in
microvessel endothelium of human brain. Neuroreport. 13:2059–2063.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mena AC, Pulido EG and Guillén-Ponce C:
Understanding the molecular-based mechanism of action of the
tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 21(Suppl
1): S3–S11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shojaei F: Anti-angiogenesis therapy in
cancer: current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmitt JM, Sommers SR, Fisher W, et al:
Sunitinib plus paclitaxel in patients with advanced esophageal
cancer: a phase II study from the Hoosier Oncology Group. J Thorac
Oncol. 7:760–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galsky MD, Hahn NM, Powles T, et al:
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial
carcinoma and as preoperative therapy for muscle-invasive bladder
cancer. Clin Genitourin Cancer. 11:175–181. 2013. View Article : Google Scholar
|
|
24
|
Gómez-Martín C, Salazar R, Montagut C, et
al: A phase I, dose-finding study of sunitinib combined with
cisplatin and 5-fluorouracil in patients with advanced gastric
cancer. Invest New Drugs. 31:390–398. 2013. View Article : Google Scholar
|
|
25
|
Wang WL, Conley A, Reynoso D, Nolden L,
Lazar AJ, George S and Trent JC: Mechanisms of resistance to
imatinib and sunitinib in gastrointestinal stromal tumor. Cancer
Chemother Pharmacol. 67(Suppl 1): S15–S24. 2011. View Article : Google Scholar
|
|
26
|
Bracci R, Maccaroni E and Cascinu S:
Transient sunitinib resistance in gastrointestinal stromal tumors.
N Engl J Med. 368:2042–2043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trochon-Joseph V, Martel-Renoir D, Mir LM,
et al: Evidence of antiangiogenic and antimetastatic activities of
the recombinant disintegrin domain of metargidin. Cancer Res.
64:2062–2069. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji BS, He L and Liu GQ: Reversal of
p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine
derivative, in doxorubicin-resistant human myelogenous leukemia
(K562/DOX) cells. Life Sci. w77:2221–2232. 2005. View Article : Google Scholar
|
|
29
|
Kawahara H, Noguchi K, Katayama K,
Mitsuhashi J and Sugimoto Y: Pharmacological interaction with
sunitinib is abolished by a germ-line mutation (1291T>C) of
BCRP/ABCG2 gene. Cancer Sci. 101:1493–1500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizuno T, Fukudo M, Terada T, et al:
Impact of genetic variation in breast cancer resistance protein
(BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab
Pharmacokinet. 27:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kunimatsu S, Mizuno T, Fukudo M and
Katsura T: Effect of P-glycoprotein and breast cancer resistance
protein inhibition on the pharmacokinetics of sunitinib in rats.
Drug Metab Dispos. 41:1592–1597. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hutchison DJ: Cross resistance and
collateral sensitivity studies in cancer chemotherapy. Adv Cancer
Res. 7:235–250. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hutchison DJ: Conference on obstacles to
the control of acute leukemia. Studies on cross-resistance and
collateral sensitivity (1962–1964). Cancer Res. 25:1581–1595.
1965.PubMed/NCBI
|
|
34
|
Cesca M, Bizzaro F, Zucchetti M and
Giavazzi R: Tumor delivery of chemotherapy combined with inhibitors
of angiogenesis and vascular targeting agents. Front Oncol.
3:2592013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu XY, Ma W, Gurung K and Guo CH:
Mechanisms of tumor resistance to small-molecule vascular
disrupting agents: treatment and rationale of combination therapy.
J Formos Med Assoc. 112:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
